247 related articles for article (PubMed ID: 33981913)
1. Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis.
Jorge R; Coelho IN; Silva-Cunha A; Fernandes Cunha GM; Scott IU; Fialho SL; Furtado JM
Am J Ophthalmol Case Rep; 2021 Jun; 22():101093. PubMed ID: 33981913
[TBL] [Abstract][Full Text] [Related]
2. Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone.
Zamora YF; Arantes T; Reis FA; Garcia CR; Saraceno JJ; Belfort R; Muccioli C
Arq Bras Oftalmol; 2015; 78(4):216-9. PubMed ID: 26375334
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series.
Verma L; Thulasidas M; Gupta A
Clin Ophthalmol; 2020; 14():4279-4285. PubMed ID: 33324033
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.
Lasave AF; Díaz-Llopis M; Muccioli C; Belfort R; Arevalo JF
Ophthalmology; 2010 Sep; 117(9):1831-8. PubMed ID: 20471684
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal clindamycin for toxoplasmic retinochoroiditis.
Sobrin L; Kump LI; Foster CS
Retina; 2007 Sep; 27(7):952-7. PubMed ID: 17891023
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis.
Kishore K; Conway MD; Peyman GA
Ophthalmic Surg Lasers; 2001; 32(3):183-92. PubMed ID: 11371084
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.
Baharivand N; Mahdavifard A; Fouladi RF
Int Ophthalmol; 2013 Feb; 33(1):39-46. PubMed ID: 23053769
[TBL] [Abstract][Full Text] [Related]
8. Atypical toxoplasmic retinochoroiditis.
Theodoropoulou S; Schmoll C; Templeton K; Dhillon B
BMJ Case Rep; 2012 May; 2012():. PubMed ID: 22669878
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal clindamycin in the treatment of unresponsive zone one toxoplasmic chorioretinitis: a case report.
Hosseini SM; Abrishami M; Mehdi Zadeh M
Iran Red Crescent Med J; 2014 Nov; 16(11):e15428. PubMed ID: 25763208
[TBL] [Abstract][Full Text] [Related]
10. [Intravitreal clindamycin injection in toxoplasma retinochoroiditis: About 9 cases in the ophthalmology department of the CHU de Bordeaux].
Handaye-Dessus A; Gattoussi S; Korobelnik JF; Delyfer MN; Rougier MB
J Fr Ophtalmol; 2021 Sep; 44(7):968-976. PubMed ID: 34247873
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of Latent Toxoplasmosis Following Dexamethasone Implant Injection.
Olson DJ; Parhiz AT; Wirthlin RS
Ophthalmic Surg Lasers Imaging Retina; 2016 Nov; 47(11):1050-1052. PubMed ID: 27842200
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal clindamycin as a therapeutic alternative in severe ocular toxoplasmosis.
Tabuenca Del Barrio L; Heras Mulero H; Mozo Cuadrado M; Fanlo Mateo P; Compains Silva E
Arch Soc Esp Oftalmol (Engl Ed); 2019 Dec; 94(12):602-604. PubMed ID: 31607401
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis.
Kim M; Kim SA; Park W; Kim RY; Park YH
Adv Ther; 2019 Aug; 36(8):2137-2146. PubMed ID: 31140122
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Injection of Sulfamethoxazole and Trimethoprim Associated with Dexamethasone as an Alternative Therapy for Ocular Toxoplasmosis.
Souza CE; Nascimento H; Lima A; Muccioli C; Belfort R
Ocul Immunol Inflamm; 2018; 26(7):1041-1044. PubMed ID: 28448726
[TBL] [Abstract][Full Text] [Related]
15. Foveal reorganization after treatment of acute foveal toxoplasmic retinochoroiditis.
Abrishami M; Hosseini SM; Momtahen S; Zamani G
J Ophthalmic Inflamm Infect; 2021 Jun; 11(1):18. PubMed ID: 34151385
[TBL] [Abstract][Full Text] [Related]
16. Development of a method to quantify clindamycin in vitreous humor of rabbits' eyes by UPLC-MS/MS: application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation.
Fernandes-Cunha GM; Gouvea DR; Fulgêncio Gde O; Rezende CM; da Silva GR; Bretas JM; Fialho SL; Lopes NP; Silva-Cunha A
J Pharm Biomed Anal; 2015 Jan; 102():346-52. PubMed ID: 25459934
[TBL] [Abstract][Full Text] [Related]
17. Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report.
Pacella F; Agostinelli E; Carlesimo SC; Nebbioso M; Secondi R; Forastiere M; Pacella E
J Med Case Rep; 2016 Oct; 10(1):282. PubMed ID: 27733187
[TBL] [Abstract][Full Text] [Related]
18. [Recurrent toxoplasmic retinochoroiditis after clindamycin treatment].
Benzina Z; Chaabouni S; Hentati N; Trigui A; Chaabouni F; Ben Salah S; Khlif H; Feki J
J Fr Ophtalmol; 2005 Nov; 28(9):958-64. PubMed ID: 16395222
[TBL] [Abstract][Full Text] [Related]
19. Morphological characteristics of ocular toxoplasmosis and its regression pattern on swept-source optical coherence tomography angiography: a case report.
Park JH; Lee SY; Lee EK
BMC Ophthalmol; 2019 Sep; 19(1):199. PubMed ID: 31488090
[TBL] [Abstract][Full Text] [Related]
20. Ocular safety of Intravitreal Clindamycin Hydrochloride Released by PLGA Implants.
Fernandes-Cunha GM; Fialho SL; da Silva GR; Silva-Cunha A; Zhao M; Behar-Cohen F
Pharm Res; 2017 May; 34(5):1083-1092. PubMed ID: 28224388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
